NASDAQ: NPCE - NeuroPace, Inc.

Yield per half year: +53.37%
Dividend yield: 0.00%
Sector: Healthcare

Share chart NeuroPace, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About NeuroPace, Inc.

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.

more details
The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-04-22
ISIN US6412881053
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.neuropace.com
Цена ао 10.43
Change price per day: +2.49% (10.43)
Change price per week: -2.82% (11)
Change price per month: -11.58% (12.09)
Change price per 3 month: -3.08% (11.03)
Change price per half year: +53.37% (6.97)
Change price per year: -18.89% (13.18)
Change price per 3 year: +40.47% (7.61)
Change price per 5 year: 0% (10.69)
Change price per 10 year: 0% (10.69)
Change price per year to date: -7.29% (11.53)
All parameters

Underestimation

Title Value Grade
P/S 4.08 4
P/BV 40.67 1
P/E 0 0
EV/EBITDA -17.8 0
Total: 3.38

Efficiency

Title Value Grade
ROA, % -30.61 0
ROE, % -159.56 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -3.38 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 94.42 9
Yield Ebitda, % 73.37 8
Yield EPS, % -65.26 0
Total: 3.4
More

Institutions Volume Share, %
KCK Limited 5621111 21.39
Orbimed Advisors LLC. 4003967 15.23
Morgan Stanley 2460716 9.36
Soleus Capital Management, L.P. 2433168 9.26
Nantahala Capital Management, LLC 2347354 8.93
Kent Lake Capital, LLC 670946 2.55
FMR, LLC 468081 1.78
Vanguard Group Inc 413106 1.57
Millennium Management LLC 172403 0.66
Geode Capital Management, LLC 115996 0.44

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Micro-Cap ETF 0.02573 17.09 1.54048
Vanguard Russell 2000 Growth ETF 0.01 23.05 0.60264
iShares Russell 2000 Growth ETF 0.00726 38.04 0.6026
ProShares UltraPro Russell2000 0.0022 89.82 1.47873
ProShares Hedge Replication ETF 0.00058 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817
0.0131.851.23



Head Job title Payment Year of birth
Dr. Martha J. Morrell Chief Medical Officer 728.68k 1957 (68 years)
Mr. Joel D. Becker CEO, President & Director 762k 1968 (57 years)
Ms. Rebecca L. Kuhn CFO, VP of Finance & Administration, Corporate Secretary and Assistant Secretary 614.91k 1961 (64 years)
Ms. Kelley Nicholas Vice President of Sales N/A
Ms. Leah Akin Acting General Counsel N/A
Mr. Dylan St. John Chief of Operations & Development

Address: United States, Mountain View. CA, 455 North Bernardo Avenue - open in Google maps, open in Yandex maps
Website: https://www.neuropace.com